Pretomanid therapeutic drug monitoring and treatment of a pediatric patient with multidrug-resistant tuberculosis

Access to bedaqualine, pretomanid, linezolid and moxifloxacin (BPaLM) for multidrug-resistant tuberculosis is limited in children <14 years old by insufficient pharmacokinetic/dosing data for pretomanid. Therapeutic drug monitoring of pretomanid at steady state in an 11-year-old, 39 kg child provides useful clinical data and exemplifies the potential for TDM to facilitate access to BPaLM for select younger children.